Sanofi

Sanofi and other major insulin manufacturers Novo Nordisk and Eli Lilly have slashed prices for a wide range of insulin products.

The CDC has recommended prioritizing infants at the highest risk for severe RSV owing to the short supply of monoclonal antibody nirsevimab.

Merck’s reinvigorated pipeline and Sanofi’s minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.

Sanofi and other major insulin manufacturers Novo Nordisk and Eli Lilly have slashed prices for a wide range of insulin products.

The CDC has recommended prioritizing infants at the highest risk for severe RSV owing to the short supply of monoclonal antibody nirsevimab.

Merck’s reinvigorated pipeline and Sanofi’s minimal patent-loss exposure placed them atop our rankings this year, while GlaxoSmithKline joined Pfizer toward the bottom.